Next, we analysed the relationship between SET overexpression and breast cancer subtypes with varying expression of HR and HER2, using another breast cancer tissue array including 100 invasive carcinoma tissues from stage II–III breast cancers. Here, ERBB2 is linked to breast carcinoma.